UNSPSC 51313709: Ketotifen fumarate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NOS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HBD503WORO, chemically known as 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one but more generally known as ketotifen fumarate, which bears US NIH Compound Identifier 3827. European Medicines Agency schedules Ketotifen fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02836MIG.

UNSPSC 51313709 Ketotifen fumarate is a Commodity code that spans pharmaceutical products procured by state and local health agencies, though recent state and local opportunities tagged under this code diverge significantly from ketotifen-specific procurement. State and local governments buy generic pharmaceuticals, over-the-counter products, and emergency-response medications through this code family, typically via competitive bidding (IFB), cooperative purchasing agreements, and requests for information. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission represent the kinds of larger, repeat buyers active in this space. Seminole County, Florida's procurement of naloxone and drug deactivation systems signals that emergency-response pharmaceuticals and community health initiatives drive recent activity, though this opportunity is unrelated to ketotifen fumarate specifically.

Geographic activity centers on Minnesota (through MMCAP's multistate reach including Oregon), Texas, and Florida. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a response deadline of July 26, 2023 (note: deadline date appears inconsistent with posting date in source); the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows activity but little recent procurement specifically for ketotifen fumarate; vendors should monitor cooperative purchasing RFPs and state health agency solicitations for pharmaceutical product lines where ketotifen may be included in broader generic drug offerings.